-Interim data from Phase 2 ReACT study of rindopepimut in recurrent GBM to be presented-
-Additional presentations on rindopepimut compassionate use experience and EGFRvIII vaccine technology-
HAMPTON, N.J., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from the rindopepimut program were published in the 2014 abstract supplement to the journal Neuro-Oncology and can be viewed online at http://neuro-oncology.oxfordjournals.org/.
- The first abstract is entitled "ReACT: A Phase 2 study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma." Data included in this abstract were as of the time of submission (June 2014). An interim update containing more comprehensive, current data from the study will be presented by David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School in a platform presentation on Friday, November 14, 2014 from 3:35 to 3:45 pm ET.
- The second abstract is entitled "Vaccination against Epidermal Growth Factor Receptor variant III in glioblastoma: the rindopepimut compassionate use experience." Data from the rindopepimut compassionate use experience will be presented by Evangelia Razis, MD, PhD, Head, 3rd Oncology Unit Hygeia Hospital, Athens, Greece in a platform presentation on Friday, November 14, 2014 from 4:05 to 4:15 pm ET.
- Rindopepimut will also be discussed in a presentation by Michael Weller, MD, Professor, Department of Neurology, University Hospital Zurich, in a Sunrise Session on Vaccine Therapy on Sunday, November 16, 2014 from 7:00 to 8:00 am ET.
- Celldex will host a conference call and live webcast on Friday, November 14, 2014 at 5:00 pm ET to review the data presented at SNO. The conference call and presentation will be webcast live over the Internet and can be accessed by logging on to the Events Calendar under the "News & Events" section of the Celldex Therapeutics website at www.celldextherapeutics.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 28183516. A replay of the call will be available approximately two hours after the live call concludes through November 21, 2014. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 28183516. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut ("rindo"; CDX-110), glembatumumab vedotin ("glemba"; CDX-011), varlilumab ("varli"; CDX-1127), CDX-1401, CDX-301 and other products and our goals for 2014. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of rindopepimut, glembatumumab vedotin and other drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Company Contact: Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 email@example.com Media Inquiries: Dan Budwick Pure Communications, Inc. (973) 271-6085 firstname.lastname@example.org
Source:Celldex Therapeutics, Inc.